MVX-5005

MVX-5005 is a preclinical oncology small-molecule drug conjugate (SMDC) being developed by MaveriX Oncology as a targeted chemo‑immunotherapy for solid tumors. It links a proprietary tumor-targeting and activation scaffold to a potent DNA‑damaging payload to enhance the safety and efficacy profile of a broadly active cytotoxic agent, while also exerting immunomodulatory and immunostimulatory effects.[1][3][5][7][11] Preclinical studies show broad single‑agent antitumor activity across solid tumors and depletion of immunosuppressive cell subsets in the tumor microenvironment that are associated with resistance to chemotherapy and immunotherapy, supporting its development as a first‑in‑class agent for multiple solid tumor indications.[1][3][5][6][9][11]